KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2025)

Ginkgo Bioworks Holdings' Research & Development history spans 6 years, with the latest figure at $50.1 million for Q4 2025.

  • For Q4 2025, Research & Development fell 34.37% year-over-year to $50.1 million; the TTM value through Dec 2025 reached $243.8 million, down 42.51%, while the annual FY2025 figure was $243.8 million, 42.51% down from the prior year.
  • Research & Development reached $50.1 million in Q4 2025 per DNA's latest filing, down from $69.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $985.0 million in Q4 2021 to a low of $50.1 million in Q4 2025.
  • Average Research & Development over 5 years is $172.5 million, with a median of $125.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: skyrocketed 1509.75% in 2021, then plummeted 81.98% in 2022.
  • A 5-year view of Research & Development shows it stood at $985.0 million in 2021, then tumbled by 81.98% to $177.5 million in 2022, then crashed by 34.08% to $117.0 million in 2023, then plummeted by 34.74% to $76.4 million in 2024, then tumbled by 34.37% to $50.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Research & Development are $50.1 million (Q4 2025), $69.4 million (Q3 2025), and $53.4 million (Q2 2025).